Perrigo Option Alert: Mar 21 $25 Calls Sweep (4) near the midpoint: 2501 vs 6502 OI

Perrigo Option Alert: Mar 21 $25 Calls Sweep (4) near the midpoint: 2501 @ $5.525 vs 6502 OI; Ref=$30.49

Perrigo

Perrigo Company

NASDAQ

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Fed's Forward Guidance

Equities

Mid Cap

News

Guidance

Movers

PRGO

SMIG

Perrigo Company shares surged after issuing financial targets for 2025 &amp; 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. &#39;Three-S&#39; plan will enhance cash flow &amp; shareholder return. Q4 results below estimates.

Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Analyst Color

Biotech

Large Cap

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

REGN

TEVA

VTRS

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Big Biopharma Trails Behind The Market: JP Morgan&#39;s 2025 Outlook on Eli Lilly, Merck, and More

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Downgrades

Price Target

Reiteration

AMPH

AMRX

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

Perrigo Co PLC

Dividends

Press Releases

Perrigo Announces Quarterly Dividend

Earnings

Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations

Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025

Opill® extends mission of breaking down birth control barriers with launch of multi-state college tour and expansion of partnerships

Perrigo Increases Quarterly Dividend by 5%

Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference

Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations

Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

Comments

Perrigo

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga